Bárcena C, Stefanovic M, Tutusaus A, Martinez-Nieto GA, Martinez L, García-Ruiz C, de Mingo A, Caballeria J, Fernandez-Checa JC, Marí M, et al: Angiogenin secretion from hepatoma cells activates hepatic stellate cells to amplify a self-sustained cycle promoting liver cancer. Sci Rep. 5:79162015. View Article : Google Scholar : PubMed/NCBI

Lin CL, Chien RN, Yeh C, Hsu CW, Chang ML, Chen YC and Yeh CT: Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: A case-control study. Scand J Gastroenterol. 49:1456–1464. 2014. View Article : Google Scholar : PubMed/NCBI

Iwazawa J, Ohue S, Hashimoto N, Muramoto O and Mitani T: Clinical utility and limitations of tumor-feeder detection software for liver cancer embolization. Eur J Radiol. 82:1665–1671. 2013. View Article : Google Scholar : PubMed/NCBI

Padhy AK and Dondi M: A report on the implementation aspects of the International Atomic Energy Agency's first doctoral coordinated research project, 'Management of liver cancer using radionuclide methods with special emphasis on trans-arterial radio-conjugate therapy and internal dosimetry'. Semin Nucl Med. 38:S5–S12. 2008. View Article : Google Scholar : PubMed/NCBI

Nagel D, Vincendeau M, Eitelhuber AC and Krappmann D: Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies. Oncogene. 33:5655–5665. 2014. View Article : Google Scholar : PubMed/NCBI

Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC and Liu LF: Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One. 7:e325422012. View Article : Google Scholar : PubMed/NCBI

Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar :

Athar M, Back JH, Kopelovich L, Bickers DR and Kim AL: Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch Biochem Biophys. 486:95–102. 2009. View Article : Google Scholar : PubMed/NCBI

Venè R, Benelli R, Minghelli S, Astigiano S, Tosetti F and Ferrari N: Xanthohumol impairs human prostate cancer cell growth and invasion and diminishes the incidence and progression of advanced tumors in TRAMP mice. Mol Med. 18:1292–1302. 2012. View Article : Google Scholar : PubMed/NCBI

Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M and Katagiri T: Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. Sci Rep. 4:73552014. View Article : Google Scholar : PubMed/NCBI

Chie WC, Blazeby JM, Hsiao CF, Chiu HC, Poon RT, Mikoshiba N, Al-Kadhimi G, Heaton N, Calara J, Collins P, et al: EORTC Quality of Life Group: International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology. 55:1122–1129. 2012. View Article : Google Scholar

Yong WK and Abd Malek SN: Xanthohumol induces growth inhibition and apoptosis in ca ski human cervical cancer cells. Evid Based Complement Alternat Med. 2015:9213062015. View Article : Google Scholar : PubMed/NCBI

Dey A, Tergaonkar V and Lane DP: Double-edged swords as cancer therapeutics: Simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov. 7:1031–1040. 2008. View Article : Google Scholar : PubMed/NCBI

Chariot A: The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 19:404–413. 2009. View Article : Google Scholar : PubMed/NCBI

Johnson RF and Perkins ND: Nuclear factor-κB, p53, and mitochondria: Regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci. 37:317–324. 2012. View Article : Google Scholar : PubMed/NCBI

He XX, Zhang YN, Yan JW, Yan JJ, Wu Q and Song YH: CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo. Tumour Biol. Aug 7–2015.Epub ahead of print.

Zhang X, Zhang H and Ye L: Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med. 147:58–66. 2006. View Article : Google Scholar : PubMed/NCBI

Dell'Eva R, Ambrosini C, Vannini N, Piaggio G, Albini A and Ferrari N: AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer. 110:2007–2011. 2007. View Article : Google Scholar : PubMed/NCBI

Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, Horejsi Z, Tan AR, Boulton SJ and Ganesan S: Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein. J Biol Chem. 288:32357–32369. 2013. View Article : Google Scholar : PubMed/NCBI

Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S and Dent P: PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biol Ther. 14:458–465. 2013. View Article : Google Scholar : PubMed/NCBI

Ciccarone F, Klinger FG, Catizone A, Calabrese R, Zampieri M, Bacalini MG, De Felici M and Caiafa P: Poly(ADP-ribosyl)ation acts in the DNA demethylation of mouse primordial germ cells also with DNA damage-independent roles. PLoS One. 7:e469272012. View Article : Google Scholar : PubMed/NCBI

Drenzek JG, Seiler NL, Jaskula-Sztul R, Rausch MM and Rose SL: Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol Oncol. 122:396–401. 2011. View Article : Google Scholar : PubMed/NCBI

Hehlgans S, Petraki C, Reichert S, Cordes N, Rödel C and Rödel F: Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiother Oncol. 108:32–39. 2013. View Article : Google Scholar : PubMed/NCBI

Srivastava AK, Singh PK, Singh D, Dalela D, Rath SK, Goel MM and Bhatt ML: Evaluation of urinary XIAP as a diagnostic biomarker of carcinoma of urinary bladder. Tumour Biol. 35:8243–8248. 2014. View Article : Google Scholar : PubMed/NCBI

Lee FA, Zee BC, Cheung FY, Kwong P, Chiang CL, Leung KC, Siu SW, Lee C, Lai M, Kwok C, et al: Randomized phase II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Am J Clin Oncol. Jun 23–2014.Epub ahead of print.

Lewis EM, Wilkinson AS, Davis NY, Horita DA and Wilkinson JC: Nondegradative ubiquitination of apoptosis inducing factor (AIF) by X-linked inhibitor of apoptosis at a residue critical for AIF-mediated chromatin degradation. Biochemistry. 50:11084–11096. 2011. View Article : Google Scholar : PubMed/NCBI

Mendivil-Perez M, Velez-Pardo C and Jimenez-Del-Rio M: TPEN induces apoptosis independently of zinc chelator activity in a model of acute lymphoblastic leukemia and ex vivo acute leukemia cells through oxidative stress and mitochondria caspase-3- and AIF-dependent pathways. Oxid Med Cell Longev. 2012:3132752012. View Article : Google Scholar

Park SY, Kim HY, Lee JH, Yoon KH, Chang MS and Park SK: The age-dependent induction of apoptosis-inducing factor (AIF) in the human semitendinosus skeletal muscle. Cell Mol Biol Lett. 15:1–12. 2010. View Article : Google Scholar

Doti N, Reuther C, Scognamiglio PL, Dolga AM, Plesnila N, Ruvo M and Culmsee C: Inhibition of the AIF/CypA complex protects against intrinsic death pathways induced by oxidative stress. Cell Death Dis. 5:e9932014. View Article : Google Scholar : PubMed/NCBI

Festa M, Capasso A, D'Acunto CW, Masullo M, Rossi AG, Pizza C and Piacente S: Xanthohumol induces apoptosis in human malignant glioblastoma cells by increasing reactive oxygen species and activating MAPK pathways. J Nat Prod. 74:2505–2513. 2011. View Article : Google Scholar : PubMed/NCBI